Showing results (61-70 of 101) with videos related to
Sort By:
Pageof 11
Journal of Acquired Immune Deficiency Syndromes (1999)|June 3, 2009
Elevated natural killer cell activity despite altered functional and phenotypic profile in Ugandans with HIV-1 clade A or clade D infectionMichael A Eller, Leigh Anne Eller, Benson J Ouma, et al.Plos One|October 11, 2012
Heterologous prime-boost regimens using rAd35 and rMVA vectors elicit stronger cellular immune responses to HIV proteins than homologous regimensSilvia Ratto-Kim, Jeffrey R Currier, Josephine H Cox, et al.NPJ Vaccines|October 17, 2024
Long term T cell response and safety of a tetravalent dengue vaccine in healthy childrenSanja Mandaric, Heather Friberg, Xavier Saez-Llorens, et al.Plos One|May 28, 2010
High-throughput high-resolution class I HLA genotyping in East AfricaRebecca N Koehler, Anne M Walsh, Eric E Sanders-Buell, et al.The American Journal of Tropical Medicine and Hygiene|April 29, 2020
Safety and Immunogenicity of an AS03B-Adjuvanted Inactivated Tetravalent Dengue Virus Vaccine Administered on Varying Schedules to Healthy U.S. Adults: A Phase 1/2 Randomized StudyLeyi Lin, Kirsten E Lyke, Michael Koren, et al.Plos One|February 10, 2015
Identification of immunodominant CD4-restricted epitopes co-located with antibody binding sites in individuals vaccinated with ALVAC-HIV and AIDSVAX B/ESilvia Ratto-Kim, Mark S de Souza, Jeffrey R Currier, et al.Journal of Immunology (Baltimore, Md. : 1950)|April 25, 2012
The Thai phase III trial (RV144) vaccine regimen induces T cell responses that preferentially target epitopes within the V2 region of HIV-1 envelopeMark S de Souza, Silvia Ratto-Kim, Weerawan Chuenarom, et al.The American Journal of Tropical Medicine and Hygiene|July 8, 2015
Safety and Immunogenicity of a Dengue Virus Serotype-1 Purified-Inactivated Vaccine: Results of a Phase 1 Clinical TrialLuis Javier Martinez, Leyi Lin, Jason M Blaylock, et al.Plos One|November 19, 2010
Phase I safety and immunogenicity evaluation of MVA-CMDR, a multigenic, recombinant modified vaccinia Ankara-HIV-1 vaccine candidateJeffrey R Currier, Viseth Ngauy, Mark S de Souza, et al.Ebiomedicine|October 4, 2023
Priming with Japanese encephalitis virus or yellow fever virus vaccination led to the recognition of multiple flaviviruses without boosting antibody responses induced by an inactivated Zika virus vaccineYifan Li, Mélanie Merbah, Suzanne Wollen-Roberts, et al.Pageof 11